Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Corso

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA RepairFarah Ballout, Heng Lu, Nadeem Bhat, et al.
Science Signaling|December 10, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Cancer Research|May 3, 2006
MET overexpression turns human primary osteoblasts into osteosarcomasSalvatore Patanè, Sofia Avnet, Nadia Coltella, et al.
Science Signaling|December 31, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 23, 2024
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer modelsElisabetta Puliga, Chiara De Bellis, Sandra Vietti Michelina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2022
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB TrialFilippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, et al.
Cell Metabolism|September 4, 2018
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted TherapiesMaria Apicella, Elisa Giannoni, Stephany Fiore, et al.
Cellular Oncology (Dordrecht, Netherlands)|February 8, 2023
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancerLorenzo Castagnoli, Simona Corso, Alma Franceschini, et al.
Scientific Reports|March 7, 2019
The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
Scientific Reports|April 26, 2020
Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA RepairFarah Ballout, Heng Lu, Nadeem Bhat, et al.
Science Signaling|December 10, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Cancer Research|May 3, 2006
MET overexpression turns human primary osteoblasts into osteosarcomasSalvatore Patanè, Sofia Avnet, Nadia Coltella, et al.
Science Signaling|December 31, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 23, 2024
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer modelsElisabetta Puliga, Chiara De Bellis, Sandra Vietti Michelina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2022
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB TrialFilippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, et al.
Cell Metabolism|September 4, 2018
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted TherapiesMaria Apicella, Elisa Giannoni, Stephany Fiore, et al.
Cellular Oncology (Dordrecht, Netherlands)|February 8, 2023
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancerLorenzo Castagnoli, Simona Corso, Alma Franceschini, et al.
Scientific Reports|March 7, 2019
The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
Scientific Reports|April 26, 2020
Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
Pageof 6